Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
Rebecca Suk Heist
No relevant relationships to disclose
Leena Gandhi
No relevant relationships to disclose
Geoffrey Shapiro
Research Funding - Merck KGaA
Naiyer A. Rizvi
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Jose Baselga
Consultant or Advisory Role - Merck KGaA
Scott B Yerganian
No relevant relationships to disclose
Karl Hsu
Employment or Leadership Position - Sanofi
Janet Ogden
Employment or Leadership Position - EMD Serono
Loïc Vincent
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Research Funding - Sanofi
Expert Testimony - Sanofi
Oliver von Richter
Employment or Leadership Position - Merck KGaA
Giuseppe Locatelli
Employment or Leadership Position - Merck Serono
Ekatherine Asatiani
Employment or Leadership Position - Merck Serono
Jeffrey R. Infante
No relevant relationships to disclose